Updated:
Cullinan Oncology
Cullinan Oncology is a biotech firm founded in 2017 by Nadim Ahmed, raising over $1B to develop targeted cancer therapies through a hub-and-spoke model.
Cullinan Oncology
Cullinan Oncology was founded in 2017 by a team including Nadim Ahmed and has since established a presence in Norwalk, Connecticut with additional offices in Cambridge, Massachusetts and La Jolla, California. The firm's wealth origin is not publicly disclosed, but its structure as a publicly traded company (NASDAQ: CGEM) provides transparency through SEC filings. Cullinan's investment strategy centers on developing novel oncology therapeutics across multiple modalities, including small molecules, antibodies, and cell therapies. The firm has disclosed positions in several clinical-stage assets, including CLN-619 (a MICA/B antibody for solid tumors) and CLN-978 (a CD19-targeted T cell engager). Geographic focus is primarily the United States, with clinical trial sites extending to Europe and Asia. As of 2025, Cullinan had raised over $1B in equity and debt financing, including a $280M public offering in 2021. The firm employs approximately 100 professionals across its three offices. In April 2024, Cullinan announced a strategic collaboration with MD Anderson Cancer Center to advance its pipeline (per Cullinan Oncology, April 2024). Cullinan's structural differentiator is its hub-and-spoke model — each drug candidate is developed in a separate subsidiary company, with Cullinan providing central functions like R&D, regulatory, and finance. This structure allows the firm to spin out or partner individual programs while maintaining control over the overall portfolio, a governance design rare among biotech firms of its size.
General information
Firm type
Asset Manager
Year founded
2017
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Norwalk
Corporate office
Norwalk, CT, United States
Additional offices
Cambridge, MA, United States · La Jolla, CA, United States
Principals
Nadim Ahmed
President and Chief Executive Officer
Jeffrey Jones
Chief Medical Officer
Jacqueline Vink
Chief Financial Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Cullinan Oncology?
Investment decisions are led by President and CEO Nadim Ahmed, with input from Chief Medical Officer Jeffrey Jones and Chief Financial Officer Jacqueline Vink. The board of directors, composed of industry and finance veterans, oversees strategic allocation. Specific investment committee details are not publicly disclosed.
How does Cullinan Oncology source its drug programs?
Cullinan sources through internal discovery, academic partnerships, and in-licensing. The hub-and-spoke model allows each subsidiary to pursue independent research while leveraging central resources. Notable collaborations include a 2024 partnership with MD Anderson Cancer Center.
Is Cullinan Oncology structured as a family office or a biotech firm?
Cullinan Oncology is a publicly traded biotech company (NASDAQ: CGEM), not a family office. While its founding capital sources are undisclosed, its public structure provides transparency through SEC filings. It operates as a traditional drug developer with a distinct subsidiary architecture.
Does Cullinan Oncology do direct investments or fund-of-funds?
Cullinan Oncology does not invest in external funds or make financial investments. It deploys capital directly into its own drug development programs. The firm's model is entirely direct — developing assets within its subsidiaries.
What investment stages does Cullinan Oncology typically target?
Cullinan focuses on preclinical through Phase II clinical stages, targeting novel oncology targets. The firm has advanced assets from discovery into clinical trials, with one program (CLN-619) in Phase I. It does not target approved drugs or late-stage commercialization.
Which sectors does Cullinan Oncology explicitly avoid?
Cullinan Oncology explicitly avoids non-oncology therapeutic areas and drug modalities outside small molecules, antibodies, and cell therapies. The firm does not invest in medical devices, diagnostics, or digital health. Its entire pipeline is focused on oncology.
Where does the underlying wealth come from for Cullinan Oncology?
The underlying wealth origin is not publicly disclosed. Cullinan Oncology raised capital from institutional investors and public markets, but the identity of its founding backers remains private. The firm's SEC filings list institutional shareholders but not its founding capital sources.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: